BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 26637775)

  • 1. Molecularly targeted therapies for acute myeloid leukemia.
    Stein EM
    Hematology Am Soc Hematol Educ Program; 2015; 2015():579-83. PubMed ID: 26637775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. <Editors' Choice> How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
    Naoe T
    Nagoya J Med Sci; 2020 May; 82(2):151-160. PubMed ID: 32581396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
    Pemmaraju N; Kantarjian H; Andreeff M; Cortes J; Ravandi F
    Expert Opin Investig Drugs; 2014 Jul; 23(7):943-54. PubMed ID: 24749672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
    Weisberg E; Meng C; Case AE; Sattler M; Tiv HL; Gokhale PC; Buhrlage SJ; Liu X; Yang J; Wang J; Gray N; Stone RM; Adamia S; Dubreuil P; Letard S; Griffin JD
    Br J Haematol; 2019 Nov; 187(4):488-501. PubMed ID: 31309543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Availability of FLT3 inhibitors: how do we use them?
    Perl AE
    Blood; 2019 Aug; 134(9):741-745. PubMed ID: 31243041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.
    Antar AI; Otrock ZK; Jabbour E; Mohty M; Bazarbachi A
    Leukemia; 2020 Mar; 34(3):682-696. PubMed ID: 31919472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia.
    Levis M
    Future Oncol; 2014; 10(9):1571-9. PubMed ID: 25145428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukemogenic potency of the novel FLT3-N676K mutant.
    Huang K; Yang M; Pan Z; Heidel FH; Scherr M; Eder M; Fischer T; Büsche G; Welte K; von Neuhoff N; Ganser A; Li Z
    Ann Hematol; 2016 Apr; 95(5):783-91. PubMed ID: 26891877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs approved for acute myeloid leukaemia in 2018.
    Kucukyurt S; Eskazan AE
    Br J Clin Pharmacol; 2019 Dec; 85(12):2689-2693. PubMed ID: 31469910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.
    Zhang H; Savage S; Schultz AR; Bottomly D; White L; Segerdell E; Wilmot B; McWeeney SK; Eide CA; Nechiporuk T; Carlos A; Henson R; Lin C; Searles R; Ho H; Lam YL; Sweat R; Follit C; Jain V; Lind E; Borthakur G; Garcia-Manero G; Ravandi F; Kantarjian HM; Cortes J; Collins R; Buelow DR; Baker SD; Druker BJ; Tyner JW
    Nat Commun; 2019 Jan; 10(1):244. PubMed ID: 30651561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib.
    Albers C; Leischner H; Verbeek M; Yu C; Illert AL; Peschel C; von Bubnoff N; Duyster J
    Leukemia; 2013 Jun; 27(6):1416-8. PubMed ID: 23392356
    [No Abstract]   [Full Text] [Related]  

  • 14. Closing in on targeted therapy for acute myeloid leukaemia.
    The Lancet Haematology
    Lancet Haematol; 2019 Jan; 6(1):e1. PubMed ID: 30612709
    [No Abstract]   [Full Text] [Related]  

  • 15. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
    Fathi AT; Chabner BA
    Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted therapy in acute myeloid leukemia.
    Daver N; Cortes J
    Hematology; 2012 Apr; 17 Suppl 1():S59-62. PubMed ID: 22507781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
    Alvarado Y; Kantarjian HM; Luthra R; Ravandi F; Borthakur G; Garcia-Manero G; Konopleva M; Estrov Z; Andreeff M; Cortes JE
    Cancer; 2014 Jul; 120(14):2142-9. PubMed ID: 24737502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial.
    Gorcea CM; Burthem J; Tholouli E
    Future Oncol; 2018 Aug; 14(20):1995-2004. PubMed ID: 29498296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlights in Hematologic Malignancy Treatments: Leukemia, Myelodysplastic Syndromes, and Allotransplant-New Drugs on the Horizon for Acute Myeloid Leukemia.
    Jurcic JG
    JAMA Oncol; 2017 Mar; 3(3):299-300. PubMed ID: 27787556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.